Other News

Physiomics have now added both posters presented by Dr Fernando Ortega and Dr Claire Villette at the AACR conference, Atlanta to their website. To view 'A Precision Dosing Application For Advanced Prostate Cancer Chemotherapy' please click here and for 'Modelling the effect of Radiotherapy on tumour growth inhibition: the head and neck tumour case' please click here....

Dr Hitesh Mistry, Principal Consultant for Physiomics was interviewed by BioNeex on Cancer drug licensing: How to use your data to make yourself an attractive partner. Please click here to watch the interview in full....

Physiomics plc (AIM: PYC), is pleased to announce that one of its long-term consultants and collaborators, Dr Hitesh Mistry, has been appointed to the editorial board of the International Journal of Radiation Oncology-Biology-Physics (RedJournal). Click here to read in full....

Physiomics' cutting edge technology is starting to catch the attention of the world of oncology according to this article in the Daily Mail...

Physiomics plc is pleased to announce that it will be attending the 30th EORTC-NCI-AACR SYMPOSIUM in Dublin 13-16 November 2018. The European Organisation for Research and Treatment of Cancer (“EORTC”) acts as a hub for a network of over 930 institutions in 30 countries focused on translational and clinical cancer research. The Symposium is co-hosted by EORTC, the National Cancer Institute (NCI) and the American Association for...

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has today posted to shareholders its Annual Report for the financial year ended 30th June 2018 and a Circular in relation to its forthcoming Annual General Meeting Please click here to read in full....

Dr Jim Millen, CEO of Physiomics, talks to Proactive Investors’ Andrew Scott about recent successes and the company’s future direction. Please click here to watch video....

Chairman and Chief Executive Officer’s Statement Introduction We are very pleased to report on a year when we generated the highest total income in the Company’s history.  Having secured the agreement with Merck KGaA in November 2017, we were able to turn our attention to our pipeline and, leveraging the publicity generated by the Merck deal we converted two large pharmaceutical clients and a biotech client in...

Physiomics is delighted to announce that it has been awarded a contract by a new European biotech client.  The value of the contract is £55k and it is expected to complete in this calendar year. Click here to read in full....

Physiomics is pleased to announce that Dr Claire Villette has joined its technical team as a Biosimulation scientist. Click here to read in full....